65 results about "Available drugs" patented technology

The invention discloses a stem cell exosome patch and its preparation method and application and belongs to the field of tissue engineering. The stem cell exosome patch comprises the following steps: stem cell is cultured and stem cell exosome is collected; a patch scaffold is prepared; and the exosome obtained is attached to the patch scaffold to prepare the stem cell exosome patch. the stem cell exosome patch obtained has natural and easily available drug sources; action site accuracy of the exosome patch can be guaranteed; effective acting time of the patch after implantation can be prolonged; and potential safety hazard can be avoided to a great extent. Through the method, the stem cell exosome patch with good biological characteristics can be obtained. The invention is a new breakthrough of establishing a biological patch in the field of tissue engineering. Meanwhile, the product also provides a feasible scheme for clinical treatment of diseases. The principle of the invention is scientific and reliable, and the technology is simple and flexible.

A handheld medication dosage calculator (100) and method for comparing an inputted, ordered medication dosage with a known medication dosage range in a database including an input device for inputting a desired drug name, indicating whether the drug is for a child or an adult, an amount of the drugs that are ordered, the body weight or body surface of the patient, an amount of drug available in standard packaging, and the available volume associated with the available drug and a computing mechanism for determining the dosage of the drug to be delivered. The handheld medication dosage calculator (100) provides warnings when the inputted amount of drug exceeds the dose range limits or is incorrect. The handheld medication dosage calculator (100) converts an inputted drug unit of measure into a desired unit of measure. The handheld medication dosage calculator (100) lists generic drug names, trademarked product names, drug classifications and cautionary drug warning information.

The present invention has its object to provide an antihypercholesterolemic or antihyperlipidemic agent, hence a therapeutic and prophylactic drug for arteriosclerosis, which is safer and more potent in cholesterol-lowering action than the hitherto-available drugs. A cholesterol-lowering composition comprising a coenzyme Q of the following formula (I) or a reduced coenzyme Q of the following formula (II) as an active ingredient: wherein n represents an integer of 6 to 11

The invention discloses a nano-structural lipid carrier pharmaceutical composition and a preparation method thereof. The pharmaceutical composition consists of the following components in percentage by weight: 0.02-1% of an insoluble drug, 0.3-15% of a solid-state lipid material, 0.5-20% of a liquid-state liquid material, 0.8-10% of a fat-soluble emulsifier, 1-15% of a water-soluble emulsifier and 39-97.38% of an aqueous solvent. The nano-structural lipid carrier pharmaceutical composition prepared by the invention can greatly overcome the shortcomings of the insoluble drug which is not easy to dissolve in water, low in oral bioavailability and the like. The preparation method is simple and controllable, good in repeatability, and an available drug delivery system is provided for the insoluble drug.

A prescription drug printing machine is used by a physician in connection with prescribing one or more prescription drugs to a patient. The printing machine has a memory unit that contains a database of information on all known available prescription drugs, including a colored pictorial representation of each of the available drugs. Each of the colored pictorial representations is a substantially similar replica of the drug it depicts. Preferably, the colored pictorial representation is an exact replica of the actual drug, containing the drug's exact color, shape and size. The printing device includes a first and second printing means for printing a prescription drug form and a patient receipt, respectively. Both of the prescription drug form and the patient receipt include the name of the drug, a colored pictorial representation, and other information. The prescribing physician inspects each of these documents for accuracy before handing them both over to the patient. Patients remit their prescription drug form to a pharmacist and retain the patient receipt for comparison with drugs that are prepared for them by the pharmacist. The printing machine has storage means for storing information concerning the prescription drug form in the memory unit of the printer, in order to keep accurate patient records. The printing device optionally includes translating means for translating the prescription drug information into a foreign language.

The present invention relates to pharmaceutical compositions for reducing essential hypertension and systemic inflammation. While many drugs have been found to treat hypertension, the currently available drugs often do not maintain reduced blood pressure at the preferred norm of 115 / 75 mm Hg or less throughout a 24 hour period. The current invention provides compositions comprising at least one hypertensive drug combined with the natural product Coenzyme Q10 (ubiquinone or CoQ10), which synergizes with the antihypertensive drugs to maintain low blood pressure throughout the day and night while generating other positive effects on the risks of cardiovascular disease, renal failure, and stroke. CoQ10 also counteracts some of the side effects of some hypertensive drugs such as tiredness, weakness, and / or liver toxicity. The invention further describes therapeutically effective methods for reducing systemic inflammation in hypertensive mammals comprising treatment with an antihypertensive composition that includes at least one angiotensin-converting enzyme inhibitor or angiotensin receptor blocker and CoQ10 (ubiquinone). The invention metrics for reducing systemic inflammation comprise the reduction of serum levels of high sensitivity C-reactive protein (CRP), Interleukin 6 (IL-6), and / or tumor necrosis factor-alpha (TNF-alpha). These antihypertensive-CoQ10 combinations will synergistically reduce both hypertension and systemic inflammation.

The invention provides a method for advanced treatment of coking wastewater, mainly solving problems existed in the prior technology, such as complex treatment processes, ineffectiveness, and difficulty in meeting a discharging standard. The method is characterized by comprising the following major steps: step one, packing a column, that is, first soaking iron scraps by using a dilute sulfuric acid and a dilute NaOH solution separately, smashing coke, mixing uniformly the iron scraps and the coke with a volume ratio of 10:1, and packing the mixture into an iron-carbon column; step two, carrying out an acidizing treatment on the coking wastewater which has gone through a two-stage biochemical treatment; step three, adding a flocculating agent into the acidized wastewater; step four, carrying out a column chromatography treatment, during which the liquid flows into the iron-carbon column from the bottom portion and flows out from the upper portion; step five, precipitating after carrying out a neutralizing treatment; and step six, repeating operations in step two to step five on supernate obtained in step five. The method for advanced treatment of coking wastewater provided by the invention has the advantages of simple equipment needed in implementation, convenient operation, good effect, quick effectiveness, cheap and easily available drugs and reagents, low cost in operation of the device, and high practicability.

The invention discloses a dropping pill of isatis root and folium isatidis and a preparing method thereof, wherein the preparing method is characterized in that: isatis root and folium isatidis are extracted in a carbon dioxide supercritical extraction method and dried under reduced pressure to generate dried paste, polyethylene glycol 4000 is added and evenly mixed, and liquid paraffin is dropped in so as to prepare the dropping pill of isatis root and folium isatidis. The dropping pill of isatis root and folium isatidis is used for treating grippe, the curative effect is obviously better than commercially-available drugs with the same kind, and better effect is obtained.

The invention relates to hydroxamic acid group-containing diarylethene LSD1 / HDACs double-target inhibitors, a preparation method thereof and application thereof in preparation of antitumor drugs, andbelongs to the technical field of medicinal chemistry. The compounds have a general formula shown in the specification, wherein 3-position or 4-position monosubstitution is preferred; R2 is preferablyOH, OCH3, F or H; R3 is preferably selected from H and CH2OH; R4 is preferably selected from H, CH3, F, or OCH3; R5 is preferably selected from H, OH, CH2OH, CH3, F and OCH3; X is N or CH; Y is N orCH. The compounds provided by the invention have relatively strong inhibitory activity on LSD1 and HDAC1 / 6, and have very good selectivity on LSD1, and the in vitro antitumor activity of the multiplecompounds on human colon cancer HCT-116 cell strains and human gastric cancer MGC-803 cell strains is superior to that of commercially available drug SAHA. A basis is provided for research and development of LSD1 / HDACs double-target inhibitor drugs, and the compounds can be used as candidates for further development or lead compounds for development of antitumor treatment drugs.

Disclosed is a system and method for targeted therapy designs which model a cancer pathway for predicting the effectiveness of targeted anti-cancer drugs. The disclosed system and method includes utilization of a computer processor allowing for the selection of a set of drugs from available drugs using approximation algorithms utilizing cell viability data associated with a testable culture of a patient's tumor for generating a probabilistic target inhibition map (PTIM) from viability data for considering the selection of a set of drugs from available drugs, and further supports a wide variety of scenarios for personalized cancer therapy, related products and services.

The invention belongs to a Chinese patent medicine and a preparation method thereof, and in particular to a swelling and pain relieving powder for parotitis and a preparation method. The invention mainly solves the technical problems of currently available drugs for the treatment of parotitis, such as long course of treatment, slow swelling relief and easy recurrence. A technical scheme adopted by the invention is as below: the swelling and pain relieving powder for parotitis is prepared from the following raw materials by weight: 8-11 parts of rhubarb, 7-13 parts of fructus evodiae, 9-12 parts of lumbricus, 4-6 parts of Coptis chinensis, 5-8 parts of Arisaema cum bile, 4-7 parts of stiff silkworm and 9-11 parts of Caulis Polygoni Multiflori. The preparation method of the swelling and pain relieving powder for parotitis is as below: first, weighing raw materials according to the above weight; and then evenly mixing the raw materials and grinding the raw materials in a mill into a 300 mesh fine powder.

The invention provides urate oxidase modified by polyethylene glycol. At least 11 of the following amino acid sites in the urate oxidase have PEG modifications: T1, K3, K4, K30, K35, K76, K79, K97, K112, K116, K120, K152, K179, K222, K231, K266, K272, K285, K291 and K293. Compared with similar drugs appearing on the market, at least 11 sites of the amino acid sites in the polyethylene glycol modified urate oxidase have PEG modifications, so that the in-vivo stability of the urate oxidase can be greatly improved and the immunogenicity is reduced under the premise of ensuring the enzyme activityto the maximum extent. The in-vivo drug effect after intramuscular injection can reach the equivalent in-vivo drug effect after intravenous injection of commercially available drugs.

The present invention relates to anthracycline derivatives that are based on an Aloe-emodin (AE) backbone attached to a glycoside (an amino sugar or amino carba-sugar). These derivatives are useful as chemotherapeutic agents. Advantageously, these derivatives are potent cytotoxic agents against a variety of anthracycline-resistant tumors. In addition, they may have reduced cardiotoxicity. As such, the novel compounds of the invention offer an advantage over currently available drugs. The present invention further relates to methods for preparing the novel Aloe-Emodin Glycoside (AEG) based derivatives, pharmaceutical compositions including such compounds, and methods of using these compounds and compositions, especially as chemotherapeutic agents for prevention and treatment of cancers.

The invention relates to the sulfonamide prodrugs of formula (I), comprising a heteroaromatic linker, to a method for producing the same, to pharmaceutical compositions containing said compounds and to their use for producing orally available drugs. The compounds according to the invention bind to carboanhydrases and inhibit these enzymes.

An aminoadamantane nitrate compound represented by formula (I) or a pharmaceutically acceptable salt thereof is disclosed for use in preparing a drug for preventing and / or treating lung diseases. Theaminoadamantane nitrate compound represented by the formula (I) or pharmaceutically acceptable salts thereof can both inhibit NMDA receptor over-activation by non-competitive binding to NMDA receptorchannels and inhibit NMDA receptor over-activation by non-competitive binding, Play anti-inflammatory and antioxidant role, but also targeted pulmonary vascular NMDA receptor release of nitric oxide,dilate pulmonary blood vessels, improve pulmonary circulation and reduce pulmonary hypertension. As such, these compounds can be used as drug for that prevention and / or treatment of lung diseases, including acute lung injury, asthma and chronic obstructive pulmonary disease, and can be combined with existing drugs to form various dosage forms with available drug carriers.

The invention discloses a formula and a production technology of a bone impediment pain-eliminating pill. The pill comprises the following 19 drugs: Rhizoma cibotii, Rhizoma Drynariae, eupolyphaga, safflower, Malaytea Scurfpea Fruit, fried eucommia ulmoides, teasel, salted west fennel, Sichuan fructus chaenomelis, Cyathula officinalis, Radix Aconiti Preparata, prepared Kusnezoff Monkshood Roots, Rhizoma Wenyujin Concisum, radix clematidis, kudzuvine roots, gentiana macrophylla, prepared licorice roots, large centipede, and caulis spatholobi. With the efficacy of tonifying the liver and kidney, strengthening tendons and bones, promoting blood circulation, warming meridians, and dredging collaterals to eliminate impediments, the pill is suitable for neck pains, shoulder pains, fingers numbness, waist pain related lower limber pains, activity limitation, intolerance of chilliness, cold limbs and other symptoms caused by lumbar diseases and cervical spondylosis. The pill has the advantages of easily available drug raw materials, low price, simple preparation, convenient administration, unique curative effect and no toxic and side effect, thus being a drug worth popularizing.

The invention relates to traditional Chinese medicine eye drops for treating trachoma. Trachoma is a chronic infectious ophthalmology disease, and symptoms of the trachoma include rough and uneven appearances which are formed on palpebral conjunctiva surfaces and similar to sand grains in form, so the disease is named 'trachoma'. The trachoma is mainly caused by bad eye health habits such as rubbing of eyes with unwashed hands. Available drugs for treating the trachoma not only are high in cost and manufacturing cost, but also can not effect a radical cure, so that itchy symptoms are always brought to patients, once patients feel itchy and rub eyes with hands, eyes are easy to infect again. Characteristics such as photophobia and lachrymation result in that medicines for oral administration can not achieve therapeutic effects easily in the process of treatment.

The invention discloses a scheduling platform, a drug management system, a combined drug allocation system and a scheduling method. The scheduling platform carries out union set fusion calculation according to a database a, a database b and a database s to obtain a database K, the database K and the database S are deployed in the drug management system of a community health service center together, drugs s1 and a1 are issued according to the database K, the drug s1 can be retrieved in the database S, and the drug a1 cannot be retrieved in the database S, so that a drug s1 request is generated, and a pharmacy terminal of the community health service center issues the drug s1; a drug a1 request is generated and sent to the cloud scheduling platform, and the cloud scheduling platform finds a drug management system of a pharmacy A, generates the drug a1 dispatch, and sends the drug a1 dispatch to the drug management system of the pharmacy A; and the drug management system of the pharmacy A carries out express delivery on the drug a1. In the whole process, new establishment of an available drug database are completed, and drug scheduling is carried out.

The invention discloses an application of tiratrocol to treatment of coxsackie virus infection. The invention provides an application of the tiratropine or derivatives thereof or pharmaceutically acceptable salts thereof or substances taking tiratropine or derivatives thereof or pharmaceutically acceptable salts thereof as active ingredients in any one of the following aspects: inhibiting coxsackie virus, treating diseases caused by coxsackie virus infection, and improving the symptoms caused by coxsackie virus infection. Based on a coxsackie virus drug screening model, an anti-coxsackie virusactive drug namely tiratrocol is screened from commercially available drugs. The tiratrocol has important clinical application value for treating diseases infected with the coxsackie virus.

The invention relates to a gliclazide sustained-release tablet which specifically comprises gliclazide, a skeleton material, a diluent and a pore-foaming agent, and the skeleton material is methacrylic acid copolymer. The gliclazide sustained release tablet provided by the invention has relatively stable dissolution and release properties, does not have a burst release phenomenon, and has a dissolution curve consistent with that of commercially available drugs; meanwhile, the gliclazide sustained release tablet disclosed by the invention has better quality stability, simple preparation process, low production cost and is suitable for industrial large-scale production.

The invention relates to a substance structure optimization guidance method and system based on a structure and pharmacokinetic properties. Ten important properties in chemical synthetic drug analysisare selected, the most similar molecular structure in research and development of commercially available drugs is matched for a compounds according to two factors of properties and structure, and anoptimization process from the molecular structure to a patent medicine is provided to guide structure optimization of new drug compound molecules. By means of the substance structure optimization guidance method and system based on the structure and pharmacokinetic properties, the most similar molecular structure in research and development of commercially available drugs can be matched for the compounds, thereby helping drug research and development personnel compare basic information of the compounds.

The invention discloses a polycyclic benzodifuran compound with a formula (I), a preparation method thereof and an application of the polycyclic benzodifuran compound as an anti-respiratory syncytialvirus (RSV) drug. The polycyclic benzodifuran compound disclosed by the invention has a relatively strong inhibiting effect on respiratory syncytial virus, and the activity of the polycyclic benzodifuran compound is superior to that of the existing commercially available drug ribavirin. Therefore, the compound has a good application prospect in treating related diseases caused by respiratory syncytial virus infection.

The invention relates to the technical field of synthetic medicine and chemical engineering, in particular to a 1,2,5-polysubstituted imidazole derivative as well as a synthetic method and applicationthereof. The structure of the 1,2,5-polysubstituted imidazole derivative is shown as a formula in the specification. In the formula, R1 or R2 is any one selected from the group consisting of a phenylgroup, a C1-C10 alkyl substituted phenyl group, a halogen substituted phenyl group, a C1-C10 alkoxy substituted phenyl group, a naphthyl group, a pyrrolylgroup, a furyl group and a thienyl group; andR3 is any one selected from the group consisting of a phenyl group, a C1-C10 alkyl substituted phenyl group, a halogen substituted phenyl group, a C1-C10 alkoxy substituted phenyl group, a naphthyl group, and a thienyl group. The synthetic method of the 1,2,5-polysubstituted imidazole derivative has the advantages of high atom economy, high regioselectivity, usage of cheap and easily available raw materials, low catalyst dosage, simple and safe operation and the like. The synthesized polysubstituted imidazole derivative widely exists in commercially available drug molecules, and is an important medical intermediate.

The invention discloses a method for using a composition used for preventing and controlling celery early blight. The method includes the following steps: a, performing crop rotation on diseased land and other vegetables for 2-3 years, and spraying a high-fat film on the ground in good time to prevent water evaporation, soil layer hardening and isolate a disease source; b, during seeding, soaking seeds at 48-50 DEG C for 30 minutes by using a solution 600 times of a stock solution, and fishing out the seeds after being cooled for drying prior to seeding; c, within 15-20 days after seeding, spraying a urea solution, and fertilizing; d, when celery grows to be 3-5cm in height, spraying a solution 900-1000 times of the stock solution every other 15 days for leaf surface spraying to treat early blight. The method is simple, products used in the method are simple in proportioning, convenient to use and good in treatment effect on the early blight, and effect is improved by 20-28% compared with conventional commercially-available drugs for preventing and controlling the early blight.

The invention discloses a synthetic method for vitamin D2 derivatives. The synthesis of the key intermediate C-24 hydroxyl group for the commercially-available drugs tacalcitol and calcipotriol is basically prepared by using a NaBH4 reduction method. The NaBH4 reduction method has the disadvantages that target product yield is about 50% and the byproduct C-24 hydroxyl epimer alcohol has no value in use. According to the invention, a byproduct 1 or a byproduct 4 respectively produced in preparation of tacalcitol or calcipotriol is used as a starting material, a Dess-Martin reagent is used as an oxidation reagent, and a reaction is carried out in an organic solvent at 0 DEG C to 100 DEG C; after the reaction is completed, cooling to room temperature is carried out and then treatment is carried out so as to obtain an intermediate 2 or 5, respectively; and after treatment, the intermediate 2 or 5 is subjected to a reduction reaction so as to obtain a compound 3 or 6, respectively. Compared with the prior art, the synthetic method provided by the invention has the advantages that raw materials are easily available; reaction conditions are mild; post-treatment is simple; the utilization rate of atoms is increased; and pollution is reduced.

The invention utilizes virtual screening strategy to seek for current market drugs as anti-schizophrenia therapy drug repurposing. Drug repurposing strategy finds new uses other than the original medical indications of existing drugs. Finding new indications for such drugs will benefit patients who are in needs for a potential new therapy sooner since known drugs are usually with acceptable safety and pharmacokinetic profiles. In this study, repurposing marketed drugs for DAAO inhibitor as new schizophrenia therapy was performed with virtual screening on marketed drugs and its metabolites. The identified and available drugs and compounds were further confirmed with in vitro DAAO enzymatic inhibitory assay.

The invention discloses a new use of nifedipine, or medically acceptable salts, esters and solvates of nifedipine in preparation of drugs for preventing and / or treating nicotine addiction, and belongsto the field of pharmaceutical technology. The use of taking nifedipine as drugs for preventing and / or treating nicotine addiction has the following advantages: (1) nifedipine can prevent nicotine addiction, accelerate a withdrawal process and prevent relapse, and the effect is obvious; (2) drug resistance on nifedipine in the aspect of preventing and treating nicotine addiction is avoided; (3) nifedipine is a clinically available drug, so that in research of drugs for preventing and / or treating nicotine addiction, cost of pre-clinical research can be greatly reduced, resources are saved, andthe research cycle can be shortened; and (4) nifedipine with working solutions is free of toxicity during animal experiments.

The invention provides a bionic silk fibroin-based self-driven electrically-controlled drug-loaded patch. The bionic silk fibroin-based self-driven electrically-controlled drug-loaded patch comprises a bionic silk fibroin-based friction nano-generator and a drug-loaded microneedle patch connected with the bionic silk fibroin-based friction nano-generator. The invention further provides a preparation method of the self-driven electric control medicine carrying patch. According to the self-driven electronic control medicine carrying patch, the conversion efficiency of converting biological mechanical energy into electric energy and the sensitivity of sensing response are improved, the friction nanometer generator has the self-cleaning function and is environmentally friendly, meanwhile, the medicine delivery efficiency is improved, and the application prospect is wide. And the electrically-controlled drug-loading patch is not limited by the drug-loading capacity, so that the range of the molecular weight of the available drug is widened, and the limitation of preparation conditions when only depending on the drug-loading microneedle array patch is reduced.

The invention discloses a mesoporous silica nanosphere, its preparation method and its application in drug loading. The preparation method comprises: adding a silicon source solution composed of an organic silicon source and a diluent into In the mixed aqueous solution in the diluent, stir and react, filter, wash and then calcined; the particle size of the prepared sample is 40-200nm, and the specific surface area is 1050-1350m 2 / g, with a pore size of 1.8‑2.4nm; it can be applied to the loading of hydrophobic drugs to realize nanonization of drugs and enhance their water solubility and dissolution rate. The method provided by the invention can avoid the use of organic templates of traditional mesoporous silica nanospheres; the raw materials are easy to obtain, the equipment is simple, and the efficiency is high; the pore wall particles are introduced into the mesoporous structure, which is beneficial to drug diffusion and loading, and reduces the weight. Crystallization, so that the in vitro dissolution rate is almost 100%, and its bioavailability is significantly higher than that of commercially available drugs, which is of great practical significance.

The invention belongs to the technical field of preparing medicines for treating diabetes and wound healing thereof, in particular to quercetin-3-O-acetic acid-(4-(3H-1,2-dithiolene-3-thione) )-phenyl ester and its application in the preparation of medicines for treating diabetes and its wound healing. The present invention uses rutin as a raw material, undergoes two substitution hydrolysis reactions, and then reduces quercetin-3-O-acetic acid to form quercetin-3-O-acetic acid, which is combined with hydrogen sulfide donor 5-(4-hydroxyphenyl)-3H-1,2 ‑Dithiolene‑3‑thione successfully prepared a compound entity capable of simultaneously treating diabetes and promoting wound healing through condensation reaction. In the HUVECs cell experiment, the cell proliferation experiment verified that it can promote the growth of HUVECs cells, and the scratch experiment and in vitro tubule formation experiment further verified that it can promote wound healing in diabetic patients. In the HepG 2 cytotoxicity experiment, it was verified that the drug had no damage to liver cells, and it was verified that the compound had a similar hypoglycemic effect to the marketed drug metformin through the treatment of insulin resistance models.